Corporate Report

The report covers the fiscal year ended September 30, 2018, when consolidated net sales reached 37,909 million yen and operating profit reached 4,391 million yen. It presents the FujiPharma 2030 vision, including leadership in women's healthcare in Japan and Asia and an overseas sales ratio of 30% by 2030. Its Sustainability section highlights women's health, companywide environmental consideration and personnel development through the virtue evaluation scheme.